DFM Funding Monitor

Developing a new treatment and companion diagnostic to improve outcomes for glioblastoma patientsbroad

GLIOBREAK · Horizon Europe grant · 2026-05-01–2028-10-31

EC contribution

€2,574,115

Total cost

€0

Beneficiaries

2

About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2025-TRANSITIONOPEN · scheme HORIZON-EIC · topic HORIZON-EIC-2025-TRANSITIONOPEN. CORDIS record →

Objective

Glioblastoma (GBM) remains a devastating brain cancer with limited treatment advances and poor survival outcomes. The GLIOBREAK project aims to develop BEA-17, a first-in-class oral small molecule that degrades epigenetic regulators LSD1 and CoREST, thereby reversing GBM immune evasion and enhancing responsiveness to immunotherapy.The main objectives are to advance BEA-17 and its biomarker-driven companion diagnostic from validated laboratory stage (TRL4) to early clinical readiness (TRL6). This will be achieved through scalable GMP manufacturing, GLP-compliant safety and pharmacokinetic studies, efficacy validation in preclinical models, biomarker discovery and validation, and regulatory preparation including orphan drug designation.GLIOBREAK directly addresses key challenges outlined in the EICT work programme by proposing a novel immuno-epigenetic therapy targeting GBM’s immunosuppressive microenvironment, combined with precision biomarker-based patient stratification to improve clinical outcomes. This aligns with Europe’s Beating Cancer Plan and EU priorities for innovative, personalized oncology medicines.By integrating fundamental biological insights with cutting-edge therapeutic and diagnostic development, GLIOBREAK aims to deliver a transformative new treatment option for GBM patients and establish a platform for expanding into other difficult-to-treat cancers, reinforcing Europe’s leadership in precision immuno-oncology.

Beneficiaries (2)

Organisation	Country	Role	EC contribution	SME
BEACTICA THERAPEUTICS AB	SE	coordinator	€1,643,722	Yes
KATHOLIEKE UNIVERSITEIT LEUVEN	BE	participant	€930,393

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries

Germany France Poland Spain Italy

Sectors

Security equipment Military vehicles Weapons & ammunition Military aircraft Warships & naval Military electronics

Sources

calls tenders awards research

I agree to receive the DFM Analysis briefing and funding alerts by email. I can unsubscribe at any time.

Website

Subscribe free

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.